The price-to-earnings ratio for Abbott Laboratories (NYSE: ABT) is 36.24x, which is above its average ratio. Moreover, the 36-month beta value for ABT is 0.72. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 7 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for ABT is 1.73B and currently, short sellers hold a 0.74% of that float. On September 24, 2024, ABT’s average trading volume was 6.14M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ABT) stock’s latest price update
Abbott Laboratories (NYSE: ABT)’s stock price has increased by 0.98 compared to its previous closing price of 113.70. However, the company has seen a -2.40% decrease in its stock price over the last five trading sessions. businesswire.com reported 2024-09-23 that CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the first patient has been enrolled in the SuperSaturated oxygen Comprehensive Observational REgistry (SSCORE). The prospective study is designed to provide further evidence of the efficacy of SuperSaturated Oxygen (SSO2) Therapy to reduce heart failure and mortality in patients suffering from left anterior descending ST-elevation myocardial in.
ABT’s Market Performance
ABT’s stock has fallen by -2.40% in the past week, with a monthly rise of 2.42% and a quarterly rise of 9.03%. The volatility ratio for the week is 1.68% while the volatility levels for the last 30 days are 1.40% for Abbott Laboratories The simple moving average for the past 20 days is 0.04% for ABT’s stock, with a 4.62% simple moving average for the past 200 days.
Analysts’ Opinion of ABT
Many brokerage firms have already submitted their reports for ABT stocks, with Piper Sandler repeating the rating for ABT by listing it as a “Overweight.” The predicted price for ABT in the upcoming period, according to Piper Sandler is $131 based on the research report published on September 19, 2024 of the current year 2024.
Goldman gave a rating of “Buy” to ABT, setting the target price at $121 in the report published on May 30th of the current year.
ABT Trading at 4.07% from the 50-Day Moving Average
After a stumble in the market that brought ABT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.61% of loss for the given period.
Volatility was left at 1.40%, however, over the last 30 days, the volatility rate increased by 1.68%, as shares surge +1.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.16% upper at present.
During the last 5 trading sessions, ABT fell by -2.40%, which changed the moving average for the period of 200-days by +10.02% in comparison to the 20-day moving average, which settled at $114.87. In addition, Abbott Laboratories saw 4.31% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABT starting from Ford Robert B, who sale 141,679 shares at the price of $116.41 back on Sep 12 ’24. After this action, Ford Robert B now owns 220,059 shares of Abbott Laboratories, valued at $16,493,218 using the latest closing price.
Robert B. Ford, the Officer of Abbott Laboratories, proposed sale 141,679 shares at $116.41 during a trade that took place back on Sep 12 ’24, which means that Robert B. Ford is holding shares at $16,492,852 based on the most recent closing price.
Stock Fundamentals for ABT
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.54 for the gross margin
The net margin for Abbott Laboratories stands at 0.14. The total capital return value is set at 0.11. Equity return is now at value 14.47, with 7.56 for asset returns.
Based on Abbott Laboratories (ABT), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at 0.54. The debt to equity ratio resting at 0.38. The interest coverage ratio of the stock is 13.09.
Currently, EBITDA for the company is 10.59 billion with net debt to EBITDA at 0.92. When we switch over and look at the enterprise to sales, we see a ratio of 5.1. The receivables turnover for the company is 5.94for trailing twelve months and the total asset turnover is 0.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.68.
Conclusion
To wrap up, the performance of Abbott Laboratories (ABT) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
